Evaluation of COX-2, EGFR, and p53 as biomarkers of non-dysplastic oral leukoplakias

Experimental and Molecular Pathology

Volumn 89, Issue 2, 2010, Pages 197-203

  Prado, Silvia Maria Díaz ^a,b   Cedrún, José Luis López ^b   Rey, Ramón Luaces ^b   Villaamil, Vanessa Medina ^b   García, Augusto Álvarez ^b   Ayerbes, Manuel Valladares ^b   Aparicio, Luis Antón ^a,b  

^a UNIVERSITY OF A CORUÑA   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

COX 2; EGFR; Molecular marker; Oral leukoplakia; P53; Quantitative real time PCR

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; PROTEIN P53; TOBACCO SMOKE; BIOLOGICAL MARKER; PTGS2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LEUKOPLAKIA; MALE; MOUTH MUCOSA; ORAL BIOPSY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SMOKING; UPREGULATION; BIOPSY; CHEMISTRY; EVALUATION STUDY; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BIOPSY; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; FEMALE; HUMANS; LEUKOPLAKIA, ORAL; MALE; MIDDLE AGED; MOUTH MUCOSA; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

NICOTIANA TABACUM;

EID: 77956450009     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2010.06.004     Document Type: Article

References (63)

1. Akita Y., Kozaki K., Nakagawa A., et al. Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity. Br. J. Dermatol. 2004, 151:472-480.
2. Ali S., El-Rayes B.F., Sarkar F.H., et al. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol. Cancer Ther. 2005, 4:1943-1951.
3. Altorki N.K., Subbaramaiah K., Dannenberg A.J. COX-2 inhibition in upper aerodigestive tract tumors. Semin. Oncol. 2004, 31(2 Suppl 7):30-36.
4. Aparicio G., Prado D., Jiménez Fonseca P., et al. Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer. Clin. Transl. Oncol. 2007, 9:694-702.
5. Banerjee A.G., Gopalakrishnan V.K., Bhattacharya I., et al. Deregulated cyclooxygenase-2 expression in oral premalignant tissues. Mol. Cancer Ther. 2002, 1:1265-1271.
6. Bennett A., Carter R.L., Stamford I.F., et al. Prostaglandin/like material extracted from squamous cell carcinomas of the head and neck. Br. J. Cancer 1980, 41:204-208.
7. Cao T., Pearman A.T., Zimmerman G.A., et al. Intracellular unesterified arachidonic acid signals apoptosis. Proc. Natl Acad. Sci. 2000, 97:11280-11285.
8. Cao Y., Prescott S.M. Many actions of cyclooxygenase-2 in cell dynamics and in cancer. J. Cell. Physiol. 2002, 190:279-286.
9. Chan G., Boyle J.O., Yang E.K., et al. Cyclooxygenase-2 expression is upregulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999, 59:991-994.
10. Chan T.A., Morin P.J., Vogelstein B., et al. Mechanisms underlying non-steroidal anti-inflammatory drug-mediated apoptosis. PNAS 1998, 95:681-686.
11. Chang H.W., Roh J.L., Jeong E.J., et al. Wnt signaling controls radiosensitivity via cyclooxygenases-2-mediated Ku expression in head and neck cancer. Int. J. Cancer 2008, 122:100-107.
12. Choe M.S., Zhang X., Shin H.J.C., et al. Interaction between epidermal growth factor receptor and cyclooxygenase 2 mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol. Cancer Ther. 2005, 4:1448-1455.
13. Dannenberg A.J., Altorki N.K., Boyle J.O., et al. Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract. Ann. NY Acad. Sci. 2001, 952:109-115.
14. Dannenberg A.J., Lippman S.M., Mann J.R., et al. Cyclooxygenases-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J. Clin. Oncol. 2005, 23:254-266.
15. Dannenberg A.J., Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003, 4:431-436.
16. Duarte E.C., Ribeiro D.C., Gomez M.V., et al. Genetic polymorphisms of carcinogen metabolizing enzymes are associated with oral leukoplakia development and p53 overexpression. Anticancer Res. 2008, 28:1101-1106.
17. Fan G.-K., Chen J., Ping F., et al. Immunohistochemical analysis of P57(kip2), p53 and hsp60 expressions in premalignant and malignant oral tissues. Oral Oncol. 2006, 42:147-153.
18. GeNorm VBA applet for Microsoft Excel [Excel macro on Internet] [cited July 2006]. Available from http://medgen.ugent.be/-jvdescomp/genorm/.
19. Goodwin J.S., Bankhurst A.D., Messner R.P. Suppression of human T-cell mitogenesis by prostaglandin: existence of a prostaglandin producing suppressor cell. J. Exp. Med. 1977, 146:1719-1731.
20. Goodwin J.S., Geuppens J.L. Regulation of immune response by prostaglandins. J. Clin. Immunol. 1983, 3:295-315.
21. Grandis J.R., Tweardy D.J., Melhem M.F. Asynchronous modulation of transforming growth factor α and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin. Cancer Res. 1998, 4:13-20.
22. Herbst R.S., Shin D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002, 94:1593-1611.
23. Holmstrup P., Vedtofte P., Reibel J., et al. Oral premalignant lesions: is a biopsy reliable?. J. Oral Pathol. Med. 2007, 36:262-266.
24. Howe L.R., Subbaramaiah K., Chung W.J., et al. Transcriptional activation of cyclooxygenase-2 in Wnt-1 transformed mouse mammary epithelial cells. Cancer Res. 1999, 59:1572-1577.
25. Jung T.K., Berlinger N.T., Juhn S.K. Prostaglandins in squamous cell carcinoma of the head and neck: a preliminary study. Laryngoscope 1985, 95:307-312.
26. Kövesi G., Szende B. Changes in apoptosis and mitotic index, p53 and ki67 expression in various types of oral leukoplakia. Oncology 2003, 65:331-336.
27. Kurokawa H., Matsumoto S., Murata T., et al. Immunohistochemical study of syndecan-1 downregulation and the expression of p53 protein or ki-67 antigen in oral leukoplakia with or without epithelial dysplasia. J. Oral Pathol. Med. 2003, 32:513-521.
28. Lawall M.A., Crivelini M.M. PCNA and p53 expression in oral leukoplakia with different degrees of keratinisation. J. Appl. Oral Sci. 2006, 14:276-280.
29. Lippman S.M., Sudbo J., Hong W.K. Oral cancer prevention and the evolution of molecular-targeted drug development. J. Clin. Oncol. 2005, 23:346-356.
30. -ΔΔCt method. Methods 2001, 25:402-408.
31. López-Martínez M., Anzola M., Cuevas N., et al. Aplicaciones clínicas del diagnóstico de las alteraciones de p53 en el carcinoma escamoso de cabeza y cuello (p53 en el CECC). Med. Oral 2002, 7:108-120.
32. Mestre J.R., Chan G., Zhang F., et al. Inhibition of cyclooxygenase-2expression An approach to preventing head and neck cancer. Ann N Y Acad Sci 1999, 889:62-71.
33. Mohan S., Epstein J.B. Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer. Oral Oncol. 2003, 39:537-546.
34. Moraitis D., Du B., de Lorenzo M.S., et al. Levels of Cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res. 2005, 65:664-670.
35. Nishimura G., Yanoma S., Satake K., et al. An experimental model of tumor dormancy therapy for advanced head and neck carcinoma. Jpn J. Cancer Res. 2000, 91:1199-1203.
36. Pandey M., Prakash O., Santhi W.S., et al. Overexpression of COX-2 gene in oral cancer is independent of stage of disease and degree of differentiation. Int. J. Oral Maxillofac. Surg. 2008, 37:379-383.
37. Raymond E., Faivre S., Armand J.P. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000, 60:15-23.
38. Renkonen J., Wolff H., Paavonen T. Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Arch. 2002, 440:594-597.
39. Rhee J.C., Khuri F.R., Shin D.M. Advances in chemoprevention of head and neck cancer. Oncologist 2004, 9:302-311.
40. Roche Applied Science [database on the Internet] [cited December 20, 2005]. Assay Design Center/ProbeFinder. Homo sapiens (Human). Available from http://www.universalprobelibrary.com.
41. Roche Applied Science [database on the Internet] [cited December 20, 2005]. Universal ProbeLibrary. Universal ProbeLibrary interest site. Assay Design Center/ProbeFInder. Homo sapiens (Human). Available from http://www.roche-applied-science.com.
42. Sakamoto T., Kondo K., Yamasoba T., et al. Elevated expression of cyclooxygenase-2 in adenocarcinoma of the parotid gland: insights into malignant transformation of pleomorphic adenoma. Ann. Otol. Rhinol. Laryngol. 2004, 113:930-935.
43. Sambrook J., Maniatis T., Fritsch E.F. Molecular Cloning: A Laboratory Manual 1989, Cold Spring Harber Laboratory Press, New York.
44. Santhi W.S., Sebastian P., Varghese B.T., et al. NF-kB and COX-2 during oral tumorigenesis and in assessment of minimal residual disease in surgical margins. Exp. Mol. Pathol. 2006, 81:123-130.
45. Santos Garcia A., Abad-Hernández M.M., Fonseca-Sánchez E., et al. Proteic expression of p53 and cellular proliferation in oral leukoplakias. Med. Oral Patol. Oral Cir. Bucal 2005, 10:1-8.
46. 2 in human colon cancer cells. Cancer Res. 1998, 8:362-366.
47. Shin D.M., Ro J.Y., Hong W.K., et al. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. 1994, 54:3153-3159.
48. Shirasuna K., Hayaskido Y., Sugiyama M., et al. Immunohistochemical localization of epidermal growth factor (EGF) and EGF receptor in human oral mucosa and its malignancy. Virchows Arch. A Pathol. Anat. Histopathol. 1991, 418:349-353.
49. Slaughter D.L., Southwick H.W., Smejal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953, 6:963-968.
50. Srinivasan M., Jewell S.D. Evaluation of TGF-alpha and EGFR expression in oral leukoplakia and oral submucous fibrosis by quantitative immunohistochemistry. Oncology 2001, 61:284-292.
51. th Spore Investigators Workshop 1999, Rockville, MD.
52. Sudbo J., Reith A. The evolution of predictive oncology and molecular-based therapy for oral cancer prevention. Int. J. Cancer 2005, 115:339-345.
53. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis. J. Natl Cancer Inst. 1998, 90:1609-1620.
54. Terakado N., Shintani S., Yano J., et al. Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma. Oral Oncol. 2004, 40:383-389.
55. Tsai W.C., Tsai S.T., Ko J.Y., et al. The mRNA profile of genes in betel quid chewing oral cancer patients. Oral Oncol. 2004, 40:418-426.
56. Tsujii M., DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 1995, 83:493-501.
57. Turini M.E., Dubois R.N. Cyclooxygenase-2: a therapeutic target. Ann Mev. Med. 2002, 53:35-57.
58. Vadlamudi R., Mandal M., Adam I., et al. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999, 18:305-314.
59. Vora H.H., Trivedi T.I., Shukla S.N., et al. p53 expression in leukoplakia and carcinoma of the tongue. Int. J. Biol. Markers 2006, 21:74-80.
60. Wiese F.W., Thompson P.A., Kadlubar F.F. Carcinogen substrate specificity of human COX-1 and COX-2. Carcinogenesis 2001, 21:5-10.
61. Williams C.S., Tsujii M., Reese J., et al. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 2000, 105:1598-1594.
62. Xie W., Herchman H.R. v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor. J. Biol. Chem. 1995, 270:27622-27628.
63. Ye F., Wu J., Dunn T., et al. Inhibition of cyclooxygenase-2 activity in head and neck cancer cells by genistein. Cancer Lett. 2004, 211:39-46.